about
Pharmacology of nucleoside and nucleotide reverse transcriptase inhibitor-induced mitochondrial toxicity.Drug interactions between HIV protease inhibitors and acid-reducing agents.Design of antiretroviral drug interaction studies.Clinical perspective on antiretroviral drug-drug interactions with the non-nucleoside reverse transcriptase inhibitor etravirine.Pharmacokinetic interactions between etravirine and non-antiretroviral drugs.Pharmacokinetics of once-daily darunavir/ritonavir in HIV-1-infected pregnant women.Pharmacokinetics of darunavir after administration of an oral suspension with low-dose ritonavir and with or without food.Mitochondrial toxic effects and ribavirin.The 2nd International Workshop on Clinical Pharmacology of HIV Therapy. April 2nd-4th 2001, Noordwijk, The Netherlands.Antiviral dynamics and sex differences of zidovudine and lamivudine triphosphate concentrations in HIV-infected individuals.Optimizing dosing strategies for the combination of atazanavir plus saquinavir.Effect of steady-state etravirine on the pharmacokinetics and pharmacodynamics of ethinylestradiol and norethindrone.The 5(th) International Workshop on Clinical Pharmacology of HIV Therapy.7th International Workshop on Clinical Pharmacology of HIV Therapy 20-22 April 2006, Lisbon, Portugal.Pharmacokinetics, safety, and tolerability of the 2- and 3-direct-acting antiviral combination of AL-335, odalasvir, and simeprevir in healthy subjects.Single- and multiple-dose pharmacokinetics and safety of pimodivir, a novel, non-nucleoside polymerase basic protein 2 subunit inhibitor of the influenza A virus polymerase complex, and interaction with oseltamivir: a Phase 1 open-label study in healShort-Duration AL-335, Odalasvir, With or Without Simeprevir, in Patients With HCV GT1 or 3 Infection Without CirrhosisNucleoside reverse transcriptase inhibitor-induced mitochondrial toxicity as an etiology for lipodystrophyEffect of food and ranitidine on saquinavir pharmacokinetics and gastric pH in healthy volunteersDrug interactions with new and investigational antiretrovirals
P50
Q33993644-458E8892-F013-43CF-BAF6-28B3E18C6C18Q37056576-FC5BFA7C-2C6F-4C22-A727-64AD45E9F645Q37447696-D765F61F-E0B0-4DD3-A40A-034B2234AE1CQ37787703-6FC56352-1AE5-4BA3-9CD3-51CD4CA0F242Q37818148-994AD7C3-D9FD-441C-9DCB-6B13D1402DC9Q39759988-ED1EC75C-B0AA-449D-89B3-87938125E57AQ42199714-10FB6150-4B0E-4873-A0DA-513C4A67B97CQ43640862-24FD9181-1B5B-4B69-953B-98D665C411DEQ43755314-21EA3559-48D3-4E36-9A79-999A7E64DD56Q44605402-0ADCE4B3-1E11-4E4D-B66C-7DFA6FB3A6B0Q44848402-D1887CB7-F3BC-4876-B991-6DDC57344CB5Q45980556-96E4471E-E76E-4E83-83B0-A85BC6410072Q47305594-46635AF5-D323-4449-BF52-B3780825A240Q52805351-0878E56E-C891-40F1-8844-C68D760D65B4Q54218677-393F5979-8EC8-4461-A58E-F13D9FEE0805Q59354759-C59973FD-18BB-4AA8-93A1-9B61EFCED2F0Q59355494-705F7C5D-7F76-41EC-936F-7704D8FC38A5Q73187624-475A40F1-D53E-417C-A815-205135C26764Q79971853-CAFCCDC4-3146-4802-9896-C7C2AD1DCEB8Q82287218-D7FBE1D5-E986-47F9-8742-41EEE6CCD8EE
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Thomas N Kakuda
@ast
Thomas N Kakuda
@en
Thomas N Kakuda
@es
Thomas N Kakuda
@nl
Thomas N Kakuda
@sl
type
label
Thomas N Kakuda
@ast
Thomas N Kakuda
@en
Thomas N Kakuda
@es
Thomas N Kakuda
@nl
Thomas N Kakuda
@sl
prefLabel
Thomas N Kakuda
@ast
Thomas N Kakuda
@en
Thomas N Kakuda
@es
Thomas N Kakuda
@nl
Thomas N Kakuda
@sl
P106
P21
P31
P496
0000-0001-6857-2572